influenza
negativesens
singlestrand
rna
viru
belong
famili
orthomyxovirida
orthomyxovirida
consist
four
genera
influenza
influenza
b
influenza
c
thogoto
virus
protein
influenza
virus
encod
gene
eight
rna
segment
influenza
virus
wide
distribut
natur
infect
wide
varieti
bird
mammal
includ
human
influenza
viru
subtyp
classifi
basi
antigen
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
ha
subtyp
na
subtyp
subtyp
found
infect
bird
waterfowl
shorebird
natur
reservoir
ai
virus
natur
host
ai
infect
associ
clinic
diseas
virus
gener
thought
evolutionari
stasi
human
rel
subtyp
influenza
virus
caus
sustain
outbreak
diseas
virus
bear
ha
gene
na
gene
circul
human
popul
twentieth
centuri
virus
appear
circul
replac
virus
turn
replac
virus
continu
circul
virus
reappear
continu
cocircul
virus
influenza
b
virus
continu
caus
epidem
human
winter
addit
season
influenza
epidem
potenti
also
exist
influenza
pandem
time
pandem
occur
influenza
strain
novel
ha
subtyp
without
novel
na
subtyp
appear
spread
suscept
human
popul
twentieth
centuri
influenza
pandem
occur
recent
emerg
swineorigin
pandem
influenza
viru
influenza
pandem
associ
sever
morbid
signific
mortal
pandem
milder
date
diseas
caus
pandem
influenza
viru
appear
sever
diseas
seen
epidem
influenza
signific
differ
age
group
affect
major
case
pandem
infect
hospit
occur
children
young
adult
highest
mortal
occur
adult
age
year
ai
virus
natur
reservoir
waterfowl
shorebird
one
sourc
novel
ha
na
subtyp
introduc
human
popul
influenza
viru
novel
ha
andor
na
introduc
human
popul
direct
spread
either
wild
bird
domest
poultri
seen
ai
viru
infect
human
altern
avian
human
influenza
virus
reassort
gener
viru
effici
spread
human
happen
pandem
pandem
influenza
viru
deriv
influenza
virus
circul
pig
rather
bird
viru
reassort
bear
gene
segment
origin
deriv
avian
human
classic
swine
influenza
virus
influenza
virus
also
infect
caus
diseas
wide
varieti
mammalian
speci
includ
swine
hors
ferret
mink
dog
seal
whale
current
circul
highli
pathogen
ai
virus
emerg
asia
also
infect
caus
lethal
infect
felid
includ
tiger
leopard
domest
cat
although
sever
anim
speci
infect
influenza
virus
natur
experiment
ideal
anim
model
studi
infect
immun
human
influenza
identifi
sever
anim
speci
permiss
infect
influenza
b
virus
vari
degre
exhibit
clinic
sign
ill
patholog
chang
respiratori
tract
similar
seen
human
influenza
chapter
discuss
main
featur
anim
model
use
evalu
influenza
vaccin
advantag
disadvantag
contribut
research
vaccin
influenza
human
also
discuss
role
anim
model
develop
vaccin
pandem
influenza
veterinari
vaccin
swine
equin
avian
canin
influenza
evalu
natur
host
discuss
vaccin
avail
epidem
season
influenza
sinc
inactiv
influenza
viru
vaccin
still
larg
first
develop
still
gener
produc
embryon
hen
egg
much
invest
recent
develop
cellbas
influenza
vaccin
least
two
licens
europ
sever
other
develop
europ
unit
state
live
attenu
influenza
vaccin
first
licens
unit
state
current
approv
annual
use
healthi
individu
year
age
serum
hemagglutin
inhibit
hai
antibodi
titer
greater
associ
protect
season
influenza
use
measur
predict
protect
efficaci
season
inactiv
influenza
viru
vaccin
correl
protect
live
attenu
vaccin
less
clearcut
vaccin
elicit
system
mucos
immun
respons
mucos
antibodi
respiratori
tract
believ
play
major
role
protect
afford
vaccin
antigen
drift
describ
gradual
chang
antigen
influenza
viru
allow
viru
escap
neutral
antibodi
alreadi
induc
prior
infect
immun
previous
circul
strain
antigen
drift
result
point
mutat
around
antibodycombin
site
ha
na
protein
influenza
viru
vaccin
unusu
one
compon
trival
vaccin
formul
may
chang
annual
keep
pace
antigen
drift
viru
long
licens
manufactur
process
use
chang
composit
vaccin
consid
strain
chang
treat
new
vaccin
approv
season
influenza
vaccin
use
human
requir
limit
test
anim
evalu
immunogen
human
requir
europ
unit
state
recent
year
resurg
interest
improv
season
influenza
vaccin
loom
threat
possibl
influenza
pandem
spur
effort
develop
vaccin
could
thwart
spread
emerg
pandem
viru
extens
preclin
character
new
vaccin
anim
necessari
mani
research
engag
effort
aim
develop
univers
influenza
vaccin
protect
epidem
pandem
strain
target
conserv
antigen
viru
nucleoprotein
np
matrix
protein
thu
elimin
need
constantli
updat
composit
annual
season
influenza
vaccin
immun
respons
candid
univers
vaccin
entir
differ
elicit
current
licens
season
inactiv
influenza
viru
vaccin
protect
immun
base
mainli
neutral
antibodi
produc
ha
protein
anim
model
differ
type
immun
respons
evalu
need
one
major
challeng
face
develop
pandem
influenza
vaccin
correl
protect
ai
virus
pandem
potenti
known
efficaci
novel
influenza
vaccin
establish
human
estim
efficaci
base
inform
glean
challeng
studi
anim
rodent
model
infecti
diseas
attract
number
scientif
practic
reason
small
rel
inexpens
purchas
hous
mani
inbr
strain
avail
batteri
immunolog
reagent
avail
speci
mice
use
influenza
vaccin
research
earliest
day
studi
influenza
viru
biolog
shortli
first
human
influenza
viru
isol
ferret
wilson
smith
colleagu
nation
institut
medic
research
london
discov
human
influenza
virus
would
caus
diseas
mice
first
adapt
speci
serial
passag
lung
subsequ
found
true
human
influenza
viru
isol
one
commonli
use
human
influenza
virus
mice
influenza
apuerto
viru
complex
passag
histori
includ
sever
passag
ferret
hundr
passag
egg
mice
cb
smith
cdc
atlanta
ga
person
commun
viru
well
adapt
mice
caus
lethal
infect
need
adapt
serial
passag
human
influenza
virus
one
major
drawback
use
mice
influenza
research
mani
mutat
aris
adapt
murin
host
alter
replic
kinet
result
abil
viru
escap
host
innat
immun
respons
influenza
virus
caus
diseas
lethal
mice
provid
use
endpoint
vaccin
efficaci
studi
depend
strain
viru
use
mice
may
becom
letharg
anorex
develop
ruffl
fur
may
also
exhibit
neurolog
symptom
infect
addit
weight
loss
often
primari
object
measur
sever
infect
bodi
temperatur
use
measur
mice
hypothermia
occur
follow
infect
mouseadapt
virus
irrespect
whether
influenza
viru
induc
morbid
mortal
mice
level
replic
influenza
virus
lung
inform
endpoint
efficaci
studi
mice
sinc
even
modest
reduct
titer
infecti
viru
lung
associ
surviv
lethal
infect
mice
immun
influenza
virus
vaccin
develop
serum
hai
neutral
antibodi
titer
correl
protect
subsequ
challeng
studi
virelizi
demonstr
antibodi
alon
could
protect
influenza
infect
mice
passiv
transfer
immun
serum
naiv
mice
result
reduct
replic
viru
lung
protect
recipi
mice
lethal
influenza
pneumon
prevent
tracheiti
replic
viru
upper
respiratori
tract
observ
passiv
transfer
serum
antibodi
reduc
pulmonari
viral
replic
viral
replic
upper
respiratori
tract
uniqu
influenza
similar
observ
report
influenza
c
viru
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
infect
measur
amount
viru
variou
tissu
case
high
level
serum
antibodi
present
exampl
vaccin
administ
adjuv
done
quantit
molecular
method
rule
possibl
ex
vivo
neutral
serum
antibodi
tissu
prepar
ex
vivo
neutral
shown
account
reduct
detect
viru
lung
mice
undergon
passiv
transfer
immun
serum
sarscov
use
nasal
bronchiolar
wash
sampl
instead
tissu
homogen
viral
quantit
also
employ
solut
issu
level
anesthesia
influenc
outcom
influenza
infect
mice
mice
infect
anesthesia
develop
pneumonia
infect
limit
upper
respiratori
tract
awak
mice
infect
volum
inoculum
administ
intranas
also
influenc
extent
viru
distribut
respiratori
tract
immunolog
lack
function
mx
gene
standard
laboratori
strain
mice
disadvantag
model
studi
innat
immun
respons
infect
import
howev
readi
avail
mice
rel
low
cost
avail
varieti
genet
background
target
genet
defect
immunolog
reagent
avail
still
make
mous
attract
heavili
util
anim
model
studi
influenza
influenza
viru
infect
hamster
nonadapt
human
influenza
virus
result
clinic
diseas
viru
replic
high
titer
nasal
turbin
lung
follow
intranas
infect
mice
hamster
repres
readili
avail
small
anim
model
use
preclin
evalu
candid
vaccin
extens
use
mice
studi
inactiv
influenza
viru
vaccin
bodi
temperatur
golden
syrian
hamster
mice
thu
hamster
use
evalu
live
attenu
temperaturesensit
vaccin
shutoff
temperatur
guinea
pig
infect
nonadapt
human
influenza
virus
although
amount
viru
need
infect
guinea
pig
ten
time
amount
need
infect
hamster
ferret
infect
guinea
pig
result
febril
ill
clinic
sign
influenza
infect
viru
isol
nasal
wash
anim
infect
influenza
ahong
virus
titer
viru
shed
nasal
secret
high
observ
follow
experiment
infect
ferret
infect
guinea
pig
influenza
viru
result
pneumonia
develop
slowli
revers
model
use
studi
effect
environment
pollut
drug
respiratori
tract
lowen
colleagu
report
guinea
pig
hartley
strain
highli
suscept
nonadapt
influenza
viru
intranas
infect
result
viru
replic
nose
lung
higher
titer
viru
recov
lung
viru
could
recov
upper
respiratori
tract
day
post
inocul
wherea
shed
declin
undetect
level
lung
day
viru
replic
associ
effect
bodi
temperatur
weight
anim
clinic
sign
ill
observ
common
laboratori
strain
rat
describ
semipermiss
influenza
infect
infant
rat
util
evalu
live
attenu
influenza
vaccin
use
extens
studi
influenza
infect
cotton
rat
sigmodon
hispidu
use
laboratori
model
sever
infecti
diseas
review
particular
cotton
rat
model
extens
use
develop
therapeut
antibodi
treatment
rsv
provid
much
use
inform
vaccin
develop
pathogen
sadowski
cowork
report
intranas
administr
human
influenza
viru
lightli
anesthet
outbr
young
adult
cotton
rat
result
viru
replic
respiratori
tract
product
pulmonari
lesion
strong
immun
respons
recent
year
renew
interest
cotton
rat
laboratori
anim
model
human
influenza
viru
infect
speciesspecif
reagent
permit
detail
analysi
viral
pathogenesi
immun
respons
speci
develop
inbr
cotton
rat
avail
advantag
model
includ
fact
cotton
rat
infect
nonadapt
human
influenza
virus
inbr
anim
avail
viru
replic
upper
lower
respiratori
tract
clinic
paramet
measur
viral
infect
result
histopatholog
chang
lung
similar
seen
natur
infect
human
date
limit
number
human
influenza
virus
evalu
cotton
rat
ferret
exquisit
suscept
infect
human
influenza
virus
initi
isol
human
influenza
viru
smith
colleagu
ferret
ferret
model
influenza
remain
sinc
fortuit
discoveri
opinion
mani
research
ferret
remain
ideal
small
anim
model
influenza
research
ferret
infect
nonadapt
human
influenza
viru
isol
influenza
viru
infect
ferret
primarili
upper
respiratori
tract
infect
infect
ferret
exhibit
clinic
sign
infect
similar
seen
human
influenza
includ
fever
rhiniti
sneez
disadvantag
ferret
model
studi
influenza
vaccin
includ
expens
special
hous
requir
limit
number
supplier
difficulti
obtain
anim
seroneg
influenza
viru
exquisit
sensit
respiratori
pathogen
eas
acquir
infect
handler
lack
speciesspecif
reagent
although
last
point
present
obstacl
evalu
hai
neutral
antibodi
respons
addit
high
bodi
temperatur
ferret
averag
temperatur
may
limit
util
evalu
temperaturesensit
live
attenu
influenza
vaccin
nonhuman
primat
use
extens
influenza
vaccin
research
practic
standpoint
anim
expens
proven
best
model
studi
vaccin
influenza
old
world
new
world
speci
monkey
evalu
model
human
influenza
infect
determin
earli
day
studi
influenza
viru
biolog
nonhuman
primat
speci
suscept
human
influenza
virus
human
rel
burnet
report
clinic
sign
infect
appar
cynomolgu
macaqu
infect
via
intratrach
rout
oppos
intranas
rout
interestingli
mortal
observ
anim
inocul
ws
egg
strain
mouseadapt
human
influenza
viru
passag
egg
burnet
report
patholog
chang
consist
seen
human
influenza
infect
observ
lung
infect
monkey
observ
intratrach
infect
monkey
might
requir
achiev
clinic
sign
infect
support
studi
conduct
saslaw
colleagu
rhesu
macaqu
intratrach
infect
rhesu
macaqu
lung
filtrat
mice
infect
mouseadapt
viru
result
clinic
sign
ill
day
post
infect
pi
resolv
day
pi
wherea
sign
ill
appar
monkey
inocul
viru
prepar
intranas
although
group
anim
show
hematolog
serolog
evid
infect
cynomolgu
macaqu
explor
model
evalu
immunogen
efficaci
immunostimul
complex
iscom
influenza
vaccin
rimmelzwaan
colleagu
cynomolgu
macaqu
inocul
intratrach
human
influenza
viru
develop
clinic
sign
ill
viru
could
recov
lung
lavag
nasal
swab
pharyng
swab
sampl
histopatholog
examin
perform
pigtail
macaqu
macaca
nemestrina
infect
recombin
human
influenza
viru
follow
viru
administr
via
trachea
tonsil
conjunctiva
anim
exhibit
clinic
sign
infect
includ
loss
appetit
weight
loss
nasal
discharg
moder
fever
histopatholog
observ
consist
progress
pneumonia
viru
recov
lung
tissu
day
pi
day
pi
new
world
monkey
includ
squirrel
cebu
monkey
evalu
model
influenza
vaccin
studi
murphi
et
al
demonstr
adult
squirrel
monkey
could
infect
intratrach
administ
human
influenza
virus
mild
ill
manifest
afebril
coryza
seen
although
radiograph
evid
pneumonia
observ
anim
shed
viru
respiratori
tract
studi
evalu
abil
ai
virus
replic
caus
ill
speci
differ
virus
caus
vari
degre
clinic
ill
influenza
virus
complet
attenu
squirrel
monkey
other
replic
effici
caus
clinic
sign
sever
similar
seen
human
influenza
infect
squirrel
monkey
employ
evalu
level
attenu
avianhuman
influenza
viru
reassort
studi
compar
replic
reassort
chimpanze
human
volunt
find
squirrel
monkey
predict
level
attenu
reassort
virus
human
cebu
apella
cebu
albifron
monkey
evalu
model
influenza
infect
grizzard
et
al
monkey
inocul
either
intranas
intratrach
two
human
influenza
virus
anew
anim
receiv
strain
develop
clinic
sign
ill
show
evid
infect
either
viru
shed
serolog
radiograph
evid
pulmonari
diseas
seen
anim
inocul
intratrach
eight
ten
anim
inocul
intratrach
anew
viru
mild
upper
respiratori
tract
ill
one
ten
anim
shed
viru
howev
anim
seroconvert
histopatholog
evid
inflamm
lung
trachea
seen
anim
inocul
intratrach
either
strain
although
lesion
anim
receiv
sever
chimpanze
consid
valuabl
anim
model
studi
infect
human
close
evolutionari
relationship
human
speci
howev
use
chimpanze
anim
model
research
logist
difficult
extrem
expens
anim
requir
longterm
care
stringent
isol
sinc
suscept
sever
human
pathogen
chimpanze
use
studi
influenza
influenza
b
virus
replic
high
titer
seroneg
chimpanze
viral
replic
associ
ill
advantag
studi
influenza
speci
includ
fact
chimpanze
bodi
temperatur
human
lower
respiratori
tract
repeatedli
sampl
safe
display
permiss
vector
vaccin
similar
human
exampl
vacciniabas
vaccin
evolutionarili
close
human
may
mean
similar
hostrang
restrict
replic
virus
may
present
could
facilit
select
live
attenu
candid
vaccin
test
human
renew
interest
use
nonhuman
primat
evalu
vaccin
pandem
influenza
see
vaccin
pandem
influenza
earli
day
clinic
test
live
attenu
vaccin
season
influenza
recogn
anim
model
could
predict
attenu
vaccin
would
allow
rapid
progress
immunogen
efficaci
test
ideal
systemat
comparison
behavior
attenu
viru
vaccin
candid
anim
model
human
need
achiev
end
research
began
address
question
late
earli
infant
rat
extens
investig
model
predict
restrict
replic
live
attenu
influenza
vaccin
human
gener
attenu
infant
rat
model
correl
attenu
human
although
except
speci
evalu
purpos
includ
mice
hamster
ferret
chimpanze
although
vaccin
safeti
fulli
assess
vaccin
administ
human
subject
regulatori
author
usual
recommend
standard
test
preclin
evalu
safeti
new
canidi
vaccin
primari
safeti
concern
inactiv
influenza
viru
vaccin
reactogen
live
attenu
influenza
vaccin
level
attenu
genet
stabil
standard
toxicolog
test
new
vaccin
candid
often
perform
rabbit
although
current
guidelin
nonclin
evalu
vaccin
recommend
toxicolog
studi
perform
anim
speci
close
reflect
immun
respons
vaccin
human
sensit
biolog
effect
vaccin
use
dose
rout
administr
studi
clinic
trial
design
result
studi
review
special
attent
experiment
detail
rout
administr
volum
quantiti
viru
inoculum
whether
anesthesia
use
particularli
live
attenu
vaccin
factor
influenc
outcom
toxic
follow
administr
high
dose
live
influenza
viru
anim
via
varieti
rout
report
literatur
exampl
administr
influenza
viru
administ
intranas
result
complet
pulmonari
consolid
death
mice
patholog
occur
despit
restrict
replic
viru
lung
tissu
henl
henl
report
inflamm
gut
damag
liver
spleen
death
mice
given
high
dose
influenza
viru
intraperiton
similar
find
observ
rat
rabbit
guinea
pig
lung
inflamm
observ
ferret
administ
high
titer
live
attenu
influenza
virus
intranas
system
sign
ill
report
human
volunt
receiv
attenu
influenza
virus
dose
exceed
studi
sign
clinic
ill
includ
fever
system
sign
appear
within
h
administr
viru
rapid
gener
appear
symptom
associ
product
influenza
viru
infect
system
symptom
correl
titer
viru
shed
respiratori
secret
occurr
respiratori
symptom
occurr
system
ill
human
follow
administr
high
dose
influenza
viru
absenc
high
level
viru
replic
may
explain
innat
immun
respons
abort
infect
epitheli
cell
current
procedur
market
approv
vaccin
season
influenza
involv
extens
safeti
test
anim
us
standard
gener
safeti
test
design
detect
extran
toxic
compon
vaccin
prepar
usual
perform
final
drug
product
mice
guinea
pig
test
perform
inactiv
live
attenu
viru
vaccin
inactiv
influenza
viru
vaccin
vaccin
administ
via
either
subcutan
intraperiton
rout
guinea
pig
test
wherea
intraperiton
rout
use
type
vaccin
vaccin
formul
must
also
certifi
free
endotoxin
new
vaccin
candid
novel
prepar
includ
vaccin
prepar
current
licens
methodolog
formul
adjuv
requir
extens
preclin
safeti
test
addit
test
repeat
dose
toxicolog
test
gener
safeti
test
test
would
appropri
depend
specif
type
vaccin
eg
demonstr
attenu
live
attenu
vaccin
compar
wildtyp
parent
viru
one
anim
speci
biodistribut
studi
plasmidbas
vaccin
ferret
use
assess
attenu
coldadapt
live
attenu
vaccin
influenza
studi
show
coldadapt
reassort
vaccin
virus
gener
human
influenza
virus
fail
replic
lower
respiratori
tract
ferret
sinc
ferret
good
model
influenza
infect
human
also
use
toxicolog
studi
influenza
vaccin
attenu
phenotyp
sever
live
attenu
influenza
vaccin
candid
evalu
use
hamster
model
small
number
temperaturesensit
coldadapt
reassort
influenza
virus
test
hamster
later
human
gener
correl
level
replic
hamster
human
howev
studi
aihuman
influenza
viru
reassort
find
hamster
accur
predict
level
attenu
virus
human
data
import
demonstr
genet
determin
attenu
influenza
virus
differ
differ
speci
nonhuman
primat
speci
extens
use
studi
safeti
influenza
vaccin
chimpanze
use
sever
studi
evalu
level
attenu
safeti
candid
live
attenu
vaccin
regulatori
author
europ
requir
neurovirul
test
live
attenu
influenza
vaccin
inactiv
vaccin
administ
intranas
sinc
influenza
virus
central
nervou
system
pathogen
human
wisdom
requir
design
determin
safeti
live
attenu
vaccin
truli
neurotrop
virus
polioviru
question
neonat
rat
recent
propos
model
studi
neurovirul
intranas
administ
influenza
vaccin
influenza
strain
evalu
model
virus
replic
brain
follow
intranas
administr
pronounc
lesion
dramat
behavior
chang
demonstr
infect
anim
vast
major
studi
conduct
anim
influenza
vaccin
research
evalu
immun
respons
candid
vaccin
although
clear
immun
respons
vaccin
anim
often
ident
may
directli
predict
seen
human
first
step
proofofprincipl
new
vaccin
establish
immunogen
anim
proceed
clinic
evalu
immun
respons
measur
anim
model
relev
desir
respons
human
studi
may
provid
use
inform
regard
regimen
rout
vaccin
guid
design
clinic
trial
well
establish
primari
correl
protect
inactiv
wholeviru
subunit
influenza
vaccin
administ
parenter
serum
antibodi
direct
ha
protein
studi
conduct
evalu
immun
respons
influenza
vaccin
done
mice
ferret
measur
antibodi
respons
anim
model
straightforward
sinc
hai
neutral
antibodi
assay
requir
speciesspecif
reagent
limit
studi
conduct
evalu
guinea
pig
model
studi
immun
influenza
viru
phair
colleagu
demonstr
infect
guinea
pig
unadapt
human
influenza
virus
result
resist
challeng
homolog
viru
passiv
transfer
hyperimmun
serum
naiv
guinea
pig
also
confer
protect
infect
howev
level
hai
antibodi
detect
serum
follow
infect
lower
observ
ferret
hamster
infect
guinea
pig
produc
detect
level
local
antibodi
nasal
secret
addit
high
level
nonspecif
inhibitor
hemagglutin
present
guinea
pig
sera
make
measur
specif
hai
antibodi
problemat
phair
et
al
howev
demonstr
guinea
pig
exhibit
delayedtyp
hypersensit
respons
influenza
infect
resembl
seen
human
although
respons
appear
involv
resist
infect
humor
immun
respons
ha
human
influenza
virus
vaccin
studi
extens
ferret
earli
studi
determin
naiv
ferret
protect
influenza
infect
vaccin
kill
viru
observ
confirm
later
studi
use
formalininactiv
vaccin
howev
kill
vaccin
administ
adjuv
naiv
ferret
provid
partial
protect
infect
thu
immun
respons
ferret
vaccin
inactiv
viru
vaccin
human
influenza
virus
appear
ident
seen
human
sinc
human
gener
requir
adjuv
achiev
protect
level
hai
antibodi
contrast
find
inactiv
influenza
virus
immun
live
influenza
viru
result
protect
subsequ
challeng
explan
differ
may
ferret
influenza
infect
primarili
upper
respiratori
tract
infect
adjuv
requir
elicit
higher
level
serum
antibodi
need
restrict
replic
viru
upper
respiratori
tract
sever
studi
demonstr
higher
level
serum
antibodi
requir
provid
protect
respiratori
virus
nose
anim
lung
recent
year
particularli
sinc
emerg
highli
pathogen
virus
asia
challeng
develop
vaccin
resurg
interest
heterosubtyp
immun
abil
immun
respons
elicit
particular
influenza
viru
protect
influenza
viru
differ
subtyp
heterosubtyp
immun
influenza
demonstr
number
studi
mice
precis
mechan
immun
clear
previous
thought
phenomenon
mediat
cellular
immun
respons
recent
studi
suggest
antibodi
primari
mediat
heterosubtyp
immun
divers
antibodi
repertoir
import
heterosubtyp
immun
also
observ
ferret
although
debat
length
time
immun
persist
mclaren
potter
report
persist
beyond
week
vaccin
anoth
studi
protect
infect
heterosubtyp
viru
observ
month
follow
immun
case
heterosubtyp
immun
prevent
infect
limit
viru
replic
follow
challeng
util
cotton
rat
model
address
issu
heterosubtyp
immun
explor
endpoint
studi
respiratori
rate
viru
replic
lung
nasal
tissu
pulmonari
histopatholog
statist
signific
reduct
respiratori
rate
seen
follow
challeng
cotton
rat
immun
either
homolog
viru
viru
differ
subtyp
week
earlier
compar
nonimmun
anim
reduct
respiratori
rate
correl
statist
signific
reduct
viru
titer
lung
nasal
tissu
immun
anim
cotton
rat
immun
heterosubtyp
viru
extent
alveol
interstiti
pneumonia
airway
debri
nonimmun
infect
anim
like
cotton
rat
immun
homolog
viru
sever
earli
peribronchiol
observ
primari
infect
peribronchiol
could
indic
memori
respons
heterosubtyp
immun
anim
howev
heterosubtypicimmun
cotton
rat
less
bronchiolar
epitheli
damag
anim
immun
homolog
viru
role
heterosubtyp
immun
prior
exposur
vaccin
human
although
infer
retrospect
analysi
data
influenza
pandem
extrem
complex
readili
determin
studi
young
infant
children
effect
preexist
immun
replic
immunogen
heterosubtyp
attenu
influenza
virus
suggest
heterosubtyp
immun
human
weak
approach
explor
develop
novel
vaccin
influenza
univers
influenza
vaccin
target
conserv
protein
viru
np
number
modal
np
dna
vaccin
baculovirusexpress
recombin
protein
peptid
recombin
protein
incorpor
hepat
b
core
antigen
test
mice
prevent
death
ill
follow
challeng
heterolog
viru
case
candid
univers
vaccin
influenza
new
anim
model
assay
measur
antibodi
cellular
respons
viral
antigen
ha
na
need
immun
respons
conserv
antigen
well
character
human
present
clear
whether
respons
accur
reflect
anim
model
undoubtedli
inform
obtain
area
futur
candid
univers
vaccin
evalu
clinic
trial
recent
also
interest
role
immun
respons
na
compon
season
vaccin
protect
relat
subtyp
influenza
includ
potenti
pandem
strain
antibodi
na
protein
modul
sever
influenza
ill
na
content
inactiv
influenza
viru
vaccin
current
standard
anim
model
also
use
evalu
efficaci
new
candid
influenza
vaccin
commonli
use
anim
model
studi
mice
ferret
mice
ferret
establish
antibodi
ha
prevent
infect
amelior
diseas
follow
challeng
influenza
viru
reduct
viru
titer
lower
respiratori
tract
follow
challeng
correl
protect
quantit
virolog
relev
measur
vaccin
efficaci
vaccin
design
gener
antibodi
respons
ha
addit
endpoint
morbid
mortal
patholog
find
may
provid
support
evid
protect
infect
diseas
although
demonstr
vaccin
efficaci
anim
model
absolut
requir
preclin
evalu
candid
vaccin
regulatori
standpoint
provid
evid
immun
respons
vaccin
biolog
relev
direct
transmiss
hpai
low
pathogen
ai
lpai
virus
bird
human
associ
mani
case
sever
morbid
mortal
rais
concern
emerg
one
virus
pandem
viru
therefor
prompt
effort
develop
vaccin
ai
virus
pandem
potenti
evalu
character
suitabl
anim
model
influenza
viru
subtyp
critic
step
develop
vaccin
sever
studi
demonstr
virus
isol
human
case
hong
kong
caus
diseas
death
mice
without
prior
adapt
virus
vari
abil
caus
diseas
death
balbc
mice
gener
fell
two
distinct
group
highli
virul
low
virul
mice
one
viru
intermedi
virul
two
studi
howev
gao
et
al
found
isol
one
highli
virul
model
lethal
dose
virus
highli
virul
mice
time
lower
low
virul
strain
replic
titer
time
higher
lung
mice
earli
cours
infect
replic
extrapulmonari
site
includ
brain
viral
antigen
observ
immunohistochemistri
lung
mice
infect
highli
virul
strain
less
virul
strain
associ
necrot
bronchi
viral
antigen
also
observ
glial
cell
neuron
brain
mice
infect
highli
virul
influenza
viru
find
also
report
gao
et
al
addit
gao
et
al
report
presenc
viral
antigen
cardiac
myofib
mice
infect
highli
virul
influenza
viru
abil
virus
replic
caus
diseas
death
mice
correl
abil
kill
chicken
relev
replic
virus
extrapulmonari
site
mice
diseas
human
clear
although
gener
correl
level
virul
mice
sever
outcom
diseas
human
observ
virus
evalu
dybe
colleagu
report
infect
mice
highli
pathogen
ai
virus
isol
scotland
influenza
itali
influenza
queretaro
influenza
england
influenza
caus
littl
diseas
balbc
mice
hpai
influenza
virus
isol
human
asia
caus
weight
loss
ruffl
fur
listless
pronounc
leukopenia
lethal
mice
without
prior
adapt
replic
outsid
respiratori
tract
studi
hpai
virus
isol
bird
singl
human
isol
less
virul
mice
lu
et
al
use
balbc
mous
model
evalu
immunogen
efficaci
vaccin
influenza
base
antigen
relat
nonpathogen
ai
viru
found
two
dose
inactiv
vaccin
requir
elicit
hai
antibodi
respons
magnitud
would
protect
human
influenza
major
vaccin
anim
addit
alum
adjuv
result
higher
level
hai
antibodi
greater
seroconvers
rate
find
gener
agre
observ
made
human
similar
vaccin
test
clinic
studi
two
dose
vaccin
necessari
achiev
accept
level
antibodi
addit
adjuv
case
instead
alum
use
studi
mice
increas
magnitud
antibodi
respons
well
seroconvers
rate
efficaci
vaccin
mice
determin
measur
level
viru
replic
lung
protect
lethal
challeng
isol
highli
virul
mice
efficaci
sever
differ
viru
vaccin
evalu
mice
case
vaccin
found
immunogen
protect
mice
review
test
phase
studi
human
inactiv
viru
vaccin
found
suboptim
immunogen
requir
high
dose
elicit
neutral
hai
antibodi
respons
administr
whole
virion
vaccin
inactiv
viru
vaccin
adjuv
increas
immunogen
mice
human
unclear
whether
data
obtain
mice
pandem
influenza
vaccin
predict
vaccin
immunogen
human
sinc
preclin
data
specif
vaccin
formul
test
human
date
report
coldadapt
live
attenu
vaccin
candid
ai
virus
evalu
preclin
studi
mice
vaccin
candid
bear
modifi
ha
na
variou
hpai
human
isol
six
intern
protein
gene
aann
coldadapt
ca
donor
viru
restrict
replic
lung
mice
compar
correspond
wildtyp
viru
found
immunogen
confer
protect
challeng
homolog
heterolog
wildtyp
virus
although
two
dose
vaccin
viru
requir
fulli
protect
mice
replic
homolog
wildtyp
virus
lung
anoth
live
attenu
coldadapt
candid
vaccin
reassort
viru
deriv
ha
low
pathogen
viru
remain
gene
coldadapt
viru
donor
viru
season
live
attenu
vaccin
use
russia
evalu
mice
singl
dose
live
vaccin
viru
evalu
similar
find
report
restrict
replic
respiratori
tract
mice
immunogen
abil
live
attenu
viru
elicit
local
iga
antibodi
respons
nasal
wash
demonstr
mice
modest
level
neutral
antibodi
detect
week
singl
dose
live
attenu
vaccin
vaccin
confer
protect
lethal
challeng
wildtyp
hpai
viru
predict
valu
mous
model
evalu
safeti
immunogen
vaccin
discuss
section
entitl
clinic
evalu
live
attenu
candid
vaccin
pandem
influenza
repres
low
pathogen
highli
pathogen
ai
virus
eurasian
north
american
lineag
replic
mice
without
prior
adapt
highli
pathogen
virus
demonstr
extrapulmonari
spread
spleen
brain
observ
hpai
isol
although
virus
detect
brain
earlier
infect
day
pi
day
de
wit
et
al
report
intranas
infect
mice
nonadapt
hpai
viru
isol
fatal
human
case
result
sever
ill
indic
weight
loss
lethargi
ruffl
fur
lethal
rate
loss
bodi
weight
similar
rang
dose
viru
viru
detect
spleen
liver
kidney
brain
well
lung
mice
model
use
evalu
immunogen
efficaci
candid
influenza
vaccin
singl
dose
iscom
vaccin
two
dose
subunit
vaccin
fail
protect
mice
lethal
infect
viru
one
except
mice
vaccin
two
dose
iscom
vaccin
exhibit
small
temporari
loss
bodi
weight
otherwis
appear
healthi
challeng
vaccin
two
dose
iscom
vaccin
result
least
reduct
viru
replic
lung
nearcomplet
reduct
extrapulmonari
replic
challeng
viru
howev
vaccin
mice
viru
still
present
lung
high
titer
munster
et
al
report
human
hpai
virus
caus
lethal
infect
mice
administ
intranas
high
dose
dose
specifi
dose
influenza
viru
isol
fatal
human
case
result
loss
bodi
weight
ruffl
fur
lethargi
respiratori
problem
day
pi
infect
mice
euthan
day
pi
wherea
mice
infect
intranas
influenza
viru
isol
human
conjunct
outbreak
sign
ill
loss
bodi
weight
observ
day
pi
influenza
viru
replic
titer
higher
compar
titer
lung
mice
infect
influenza
viru
isol
brain
spleen
liver
kidney
infect
anim
influenza
viru
isol
brain
one
three
mice
detect
organ
examin
histopatholog
find
mice
infect
influenza
viru
includ
necrosi
inflamm
throughout
respiratori
tract
pronounc
trachea
becam
progress
milder
bronchi
bronchiol
alveoli
contrast
lesion
respiratori
tract
observ
one
four
mice
infect
influenza
viru
character
mild
moder
cell
necrosi
neutrophil
infiltr
trachea
bronchi
bronchiol
lesion
observ
upon
histopatholog
examin
brain
heart
spleen
liver
kidney
mice
infect
either
viru
viral
antigen
express
limit
tissu
respiratori
tract
mice
infect
either
viru
abund
mice
infect
influenza
viru
rigoni
colleagu
report
hpai
virus
isol
chicken
ostrich
could
infect
replic
mice
without
adapt
associ
diseas
sign
vari
sever
bronchiti
tracheiti
alveol
brain
lesion
observ
mice
infect
three
hpai
influenza
virus
howev
influenza
viru
caus
sever
lesion
spread
rapidli
lung
brain
two
virus
influenza
influenza
low
pathogen
virus
replic
high
titer
upper
lower
respiratori
tract
mice
lethal
even
high
dose
immunogen
virus
also
evalu
mice
sever
reassort
virus
bear
ha
na
gene
avian
influenza
virus
intern
protein
gene
describ
jadhao
et
al
pappa
et
al
report
evalu
eggbas
reassort
influenza
viru
vaccin
mice
reassort
gener
deriv
ha
low
pathogen
viru
na
low
pathogen
viru
vaccin
gener
ha
na
low
pathogen
viru
mice
immun
two
dose
formalininactiv
vaccin
without
alum
mount
serum
hai
antibodi
respons
increas
second
vaccin
antibodi
respons
gener
higher
vaccin
administ
adjuv
mice
receiv
two
dose
vaccin
protect
lethal
challeng
highli
pathogen
influenza
virus
evalu
vaccin
clinic
trial
plan
immunogen
efficaci
cellbas
avian
influenza
split
virion
vaccin
deriv
hpai
viru
studi
mice
low
titer
hai
antibodi
detect
sera
two
dose
ha
titer
gener
higher
vaccin
administ
adjuv
vaccin
mice
shed
significantli
less
viru
unvaccin
anim
follow
intranas
challeng
hpai
viru
protect
diseas
weight
loss
vaccin
also
confer
signific
protect
lethal
challeng
vaccin
test
phase
clinic
trial
sixti
healthi
adult
two
dose
administ
without
adjuv
serum
hai
neutral
antibodi
titer
two
dose
low
higher
individu
receiv
adjuv
vs
dose
vs
dose
antibodi
secret
cell
also
detect
individu
detect
hai
neutral
antibodi
titer
associ
product
mous
model
also
employ
evalu
attenu
immunogen
protect
efficaci
candid
coldadapt
live
attenu
influenza
vaccin
subtyp
ha
na
gene
vaccin
viru
deriv
low
pathogen
ai
viru
achickenbritish
six
intern
protein
gene
aann
ca
viru
backbon
mice
vaccin
viru
caus
weight
loss
restrict
replic
lower
respiratori
tract
compar
low
pathogen
wildtyp
parent
viru
antigen
relat
hpai
wildtyp
viru
appear
delay
replic
kinet
upper
respiratori
tract
compar
wildtyp
parent
viru
singl
dose
ca
vaccin
viru
immunogen
mice
provid
complet
protect
lethal
pulmonari
replic
follow
challeng
influenza
virus
north
american
lineag
two
dose
vaccin
requir
confer
protect
influenza
virus
eurasian
lineag
human
infect
ai
virus
first
report
although
ill
infect
individu
rel
mild
still
concern
pandem
potenti
virus
virus
subtyp
highli
preval
bird
pathogen
human
avian
influenza
virus
mice
studi
sever
laboratori
view
establish
anim
model
use
studi
strategi
prevent
pandem
influenza
includ
vaccin
antivir
drug
influenza
virus
replic
respiratori
tract
mice
without
prior
adapt
serial
passag
aquailhong
viru
mice
result
increas
virul
extrapulmonari
spread
lethal
viru
intranas
infect
mice
data
differ
laboratori
use
viru
infect
mice
consist
factor
influenc
outcom
infect
anesthesia
dose
volum
rout
viru
administr
passag
histori
difficult
compar
studi
complet
inform
provid
exampl
studi
report
lu
et
al
human
influenza
ahong
viru
replic
effici
lung
mice
fail
caus
death
sign
diseas
signific
weight
loss
spread
extrapulmonari
site
howev
leneva
et
al
report
infect
mice
viru
result
mortal
signific
weight
loss
surviv
mice
discord
studi
mice
anesthet
metofan
infect
rout
use
viru
propag
embryon
egg
approxim
dose
inoculum
volum
use
state
either
studi
clear
viru
lethal
one
studi
similarli
lethal
challeng
mice
human
influenza
ahong
viru
report
part
studi
determin
efficaci
liposom
vaccin
although
viru
caus
diseas
lethal
hand
investig
laboratori
deliv
viru
intranas
anesthet
mice
howev
studi
report
ernst
et
al
mice
anesthet
intraperiton
ketaminexylazin
wherea
two
studi
inhal
anesthesia
use
may
result
lighter
state
anesthesia
mous
model
use
evalu
level
attenu
protect
efficaci
candid
coldadapt
live
attenu
vaccin
bear
ha
na
influenza
viru
intern
protein
gene
influenza
aann
coldadapt
viru
live
attenu
vaccin
restrict
replic
protect
mice
challeng
homolog
heterolog
wildtyp
influenza
virus
like
highli
pathogen
ai
virus
fulli
reconstruct
recombin
pandem
influenza
viru
highli
lethal
mice
without
prior
adapt
mean
time
death
mice
infect
intranas
day
howev
contrast
highli
pathogen
influenza
virus
viru
detect
extrapulmonari
tissu
histopatholog
find
includ
necrot
bronchiti
bronchiol
moder
sever
alveol
sever
peribronchi
alveolar
edema
mous
model
appear
potenti
use
evalu
pandem
influenza
vaccin
ai
virus
studi
mice
date
replic
without
adapt
although
outcom
infect
ai
virus
clearli
differ
depend
particular
viru
studi
also
laboratori
studi
conduct
import
ai
virus
continu
evalu
mice
use
standard
inocul
procedur
dose
measur
endpoint
util
model
maxim
evalu
pandem
influenza
vaccin
although
pandem
influenza
vaccin
develop
effort
focus
subtyp
ai
caus
infect
human
name
virus
theori
ai
virus
subtyp
potenti
caus
pandem
therefor
prudent
develop
anim
model
studi
pathogen
virus
evalu
experiment
vaccin
may
need
futur
concern
regard
pandem
potenti
ai
virus
sinc
virus
highli
preval
mani
avian
speci
around
world
high
propens
reassort
viru
implic
donor
intern
protein
gene
ai
virus
emerg
addit
serolog
evid
human
infect
ai
virus
china
replic
pathogen
immunogen
sever
ai
virus
studi
mice
fourteen
tempor
antigen
divers
ai
virus
variou
na
subtyp
eurasian
north
american
lineag
evalu
balbc
mice
follow
intranas
inocul
viru
replic
vari
effici
observ
respiratori
tract
mice
eleven
virus
replic
lower
respiratori
tract
ten
upper
respiratori
tract
one
virus
fail
replic
detect
level
mice
higher
titer
virus
observ
lung
mice
compar
nasal
turbin
two
virus
hong
kong
caus
signific
weight
loss
ill
death
mice
replic
appear
limit
respiratori
tract
ai
virus
replic
well
lung
elicit
high
neutral
antibodi
titer
infect
mice
immunogen
virus
correl
effici
replic
respiratori
tract
crossreact
neutral
antibodi
accur
predictor
protect
live
attenu
coldadapt
candid
vaccin
gener
three
ai
virus
studi
immunogen
efficaci
candid
vaccin
evalu
mice
singl
intranas
dose
vaccin
viru
elicit
serum
neutral
hai
antibodi
fulli
protect
mice
replic
wildtyp
parent
ai
viru
lower
respiratori
tract
crossreact
antibodi
titer
heterolog
virus
significantli
lower
homolog
parent
viru
second
dose
vaccin
mice
boost
antibodi
titer
improv
crossprotect
heterolog
ai
virus
seen
initi
studi
mice
level
neutral
antibodi
elicit
candid
vaccin
poor
predictor
abil
crossprotect
antigen
distinct
ai
virus
candid
coldadapt
vaccin
elicit
broadest
crossprotect
respons
vaccin
viru
current
undergo
evalu
human
clinic
trial
abil
limit
number
ai
subtyp
replic
caus
diseas
ferret
investig
surprisingli
behavior
subtyp
virus
studi
zitzow
colleagu
demonstr
two
influenza
virus
isol
human
case
infect
hong
kong
capabl
replic
respiratori
tract
also
brain
spleen
intestin
ferret
viru
replic
associ
clinic
sign
diseas
sever
lethargi
sneez
rhiniti
hind
limb
paresi
case
diarrhea
virus
lethal
ferret
howev
hierarchi
sever
diseas
seen
differ
isol
upon
infect
mice
observ
ferret
influenza
equal
virul
intranas
infect
ferret
wherea
viru
virul
mice
viru
sever
studi
mice
signific
respect
human
diseas
sign
extrapulmonari
replic
virus
ferret
clear
particularli
sinc
studi
zitzow
et
al
report
isol
human
influenza
viru
brain
ferret
follow
intranas
infect
similar
studi
conduct
use
human
avian
virus
isol
govorkova
et
al
evalu
four
human
influenza
isol
nine
avian
isol
asia
wide
spectrum
infect
sever
diseas
lethal
observ
ferret
inocul
virus
virus
isol
human
two
avian
isol
caus
sever
diseas
ferret
lethal
howev
difficult
draw
gener
conclus
regard
behavior
virus
model
small
number
anim
use
two
anim
per
group
one
virus
test
variabl
infect
virus
examin
exampl
although
influenza
viru
caus
sever
diseas
two
two
inocul
ferret
lethal
one
anim
viru
recov
nasal
wash
contrast
influenza
viru
also
lethal
one
two
ferret
inocul
recov
lung
brain
spleen
intestin
anim
similarli
main
et
al
evalu
isol
asia
use
ferret
model
although
virus
use
studi
differ
use
govorkova
et
al
except
similar
find
report
human
isol
caus
sever
diseas
lethal
ferret
small
number
anim
use
three
per
group
isol
test
variabl
infect
sever
diseas
observ
studi
conduct
zitzow
et
al
gross
patholog
chang
observ
ferret
infect
highli
virul
hpai
virus
includ
focal
area
red
lung
consolid
lung
rare
discolor
liver
petechia
liver
lesion
intestin
kidney
main
et
al
report
presenc
hemorrhag
adipos
tissu
surround
liver
kidney
bladder
twothird
infect
ferret
histopatholog
find
lung
infect
ferret
includ
acut
bronchiol
bronchopneumonia
interstiti
pneumonia
suppur
exud
bronchi
bronchiol
adjac
alveolar
space
promin
epitheli
necrosi
mark
intraalveolar
edema
day
pi
bronchiti
bronchiol
pneumonia
observ
day
pi
inflammatori
chang
also
evid
brain
ferret
infect
highli
virul
hpai
virus
day
pi
includ
glial
nodul
perivascular
infiltr
lymphocyt
polymorphonuclear
leukocyt
brain
parenchyma
neuronophagia
lymphocyt
infiltr
choroid
plexu
viral
antigen
observ
immunohistochemistri
neuron
area
brain
inflamm
govorkova
et
al
report
histopatholog
chang
liver
includ
diffus
vacuol
hepatocellular
cytoplasm
mononuclear
infiltr
periport
hemorrhag
hepatocellular
necrosi
gener
virus
isol
avian
speci
caus
less
sever
diseas
isol
human
number
ferret
inocul
viru
small
ferret
outbr
speci
signific
variabl
data
viru
replic
clinic
ill
difficult
interpret
scientif
commun
experi
behavior
ai
virus
anim
model
would
prudent
compar
new
isol
wellcharacter
strain
studi
pathogen
one
model
ferret
model
also
use
evalu
efficaci
sever
experiment
inactiv
live
attenu
vaccin
influenza
inactiv
vaccin
immunogen
protect
ferret
model
howev
inactiv
vaccin
test
clinic
trial
suboptim
immunogen
attenu
coldadapt
live
attenu
vaccin
demonstr
ferret
vaccin
candid
also
immunogen
protect
challeng
homolog
heterolog
wildtyp
virus
ferret
protect
lethal
infect
level
replic
challeng
viru
lung
tissu
endpoint
use
evalu
efficaci
model
van
riel
et
al
demonstr
pattern
attach
influenza
human
isol
respiratori
tract
ferret
similar
seen
human
respiratori
tract
viru
attach
predominantli
type
ii
pneumocyt
alveolar
macrophag
noncili
cuboid
epitheli
cell
termin
bronchiol
lower
respiratori
tract
becam
progress
rarer
proxim
ie
toward
trachea
pattern
viru
attach
predominantli
lower
respiratori
tract
thought
relat
distribut
sialic
acid
receptor
howev
investig
found
influenza
virus
abl
infect
ex
vivo
cultur
human
upper
respiratori
tract
ie
nasopharyng
adenoid
tonsillar
tissu
despit
lack
sialic
acid
receptor
tissu
tropism
influenza
virus
respiratori
tract
human
speci
remain
equivoc
studi
number
differ
isol
evalu
larger
number
anim
need
behavior
ai
virus
subtyp
studi
ferret
human
isol
highli
pathogen
influenza
virus
replic
higher
titer
upper
lower
respiratori
tract
ferret
low
pathogen
influenza
virus
isol
human
virus
also
replic
nonrespiratori
tissu
isol
caus
sever
ill
includ
signific
weight
loss
caus
neurolog
symptom
lethal
ferret
inocul
anoth
highli
pathogen
ai
viru
low
pathogen
virus
evalu
studi
caus
sever
diseas
lethal
model
joseph
et
al
demonstr
pattern
antigen
related
subtyp
ai
virus
determin
use
postinfect
ferret
sera
similar
observ
mice
ferret
model
use
evalu
attenu
immunogen
efficaci
ca
live
attenu
vaccin
viru
vaccin
viru
restrict
replic
upper
respiratori
tract
ferret
replic
detect
level
lung
brain
neutral
antibodi
detect
sera
ferret
immun
singl
dose
ca
vaccin
week
immun
second
dose
vaccin
provid
boost
antibodi
respons
two
dose
vaccin
significantli
reduc
replic
homolog
heterolog
highli
pathogen
influenza
virus
lung
ferret
prevent
spread
brain
olfactori
bulb
ferret
immun
inactiv
vaccin
deriv
reassort
base
hpai
alum
adjuv
mount
serum
hai
gmt
neutral
antibodi
rang
respons
two
dose
vaccin
crossreact
hai
titer
heterolog
eurasian
north
american
virus
detect
low
titer
vaccin
ferret
result
reduc
sign
ill
shed
viru
upper
lower
respiratori
tract
system
spread
follow
challeng
hpai
report
scientif
literatur
describ
replic
clinic
sign
result
infect
ferret
ai
subtyp
hinshaw
et
al
demonstr
ai
virus
subtyp
well
viru
isol
seal
replic
upper
respiratori
tract
ferret
elicit
low
undetect
level
antibodi
none
ai
isol
test
caus
sign
diseas
infect
ferret
replic
pathogenesi
immunogen
ai
virus
subtyp
evalu
ferret
model
follow
evalu
mous
model
infect
four
ai
virus
subtyp
replic
vari
degre
mice
studi
ferret
mice
virus
replic
lower
titer
upper
respiratori
tract
lung
although
differ
titer
much
less
mice
lower
titer
ferret
vs
differ
seen
mice
four
virus
replic
peak
titer
ferret
lung
although
peak
titer
occur
differ
timepoint
postinfect
transient
weight
loss
fever
observ
ferret
infect
virus
lethal
mice
also
ferret
receiv
influenza
viru
caus
sign
ill
mice
ferret
infect
influenza
exhibit
weight
loss
fever
unlik
mockinfect
ferret
fail
gain
weight
period
observ
antibodi
respons
elicit
infect
ferret
gener
correl
seen
mice
mous
model
antibodi
respons
correl
viru
replic
ferret
model
live
attenu
coldadapt
ai
candid
vaccin
virus
attenu
compar
correspond
wildtyp
viru
none
vaccin
virus
caus
sign
ill
ferret
replic
lung
singl
intranas
dose
vaccin
virus
elicit
serum
neutral
hai
antibodi
ferret
mice
confer
complet
protect
lower
respiratori
tract
follow
wildtyp
viru
challeng
level
neutral
antibodi
induc
ferret
vaccin
virus
accur
predict
outcom
challeng
heterolog
virus
ai
virus
gener
behav
similar
fashion
ferret
mice
speciesspecif
differ
crossreact
antibodi
respons
observ
reconstruct
influenza
viru
replic
high
titer
upper
respiratori
tract
ferret
follow
intranas
inocul
inocul
ferret
exhibit
sever
sign
diseas
includ
lethargi
anorexia
sneez
rhinorrhea
sever
weight
loss
high
fever
day
pi
two
three
anim
succumb
infect
day
unlik
highli
pathogen
virus
ferret
viral
replic
detect
tissu
outsid
respiratori
tract
necrot
bronchiol
moder
sever
alveol
edema
observ
lung
infect
ferret
day
pi
presenc
viral
antigen
upper
lower
portion
bronchi
bronchial
bronchiolar
epithelium
hyperplas
epithelium
within
alveoli
observ
littl
interest
influenza
infect
immun
cat
recent
reemerg
highli
pathogen
avian
virus
asia
report
number
big
cat
name
tiger
leopard
zoo
thailand
becam
infect
hpai
virus
appar
fed
infect
chicken
carcass
infect
mani
felid
fatal
later
anecdot
report
infect
domest
cat
area
outbreak
infect
avian
popul
contribut
surg
interest
influenza
cat
pattern
attach
human
influenza
viru
respiratori
tract
tissu
cat
similar
seen
human
tissu
experiment
infect
european
short
hair
cat
viru
isol
human
vietnam
result
clinic
diseas
viru
replic
respiratori
extrapulmonari
tissu
patholog
chang
consist
infect
human
clinic
sign
includ
signific
elev
bodi
temperatur
decreas
activ
conjunct
labor
breath
seen
cat
experiment
infect
intratrach
feed
infect
chick
similar
diseas
symptom
observ
sentinel
cat
becam
infect
hous
cat
infect
intratrach
ill
contact
cat
becam
appar
day
later
cat
infect
via
intratrach
rout
peak
viral
titer
throat
swab
intratrach
infect
cat
wherea
peak
titer
observ
nasal
swab
rang
viru
also
recov
rectal
swab
cat
infect
feed
infect
chick
titer
viru
sampl
vari
wide
addit
cat
infect
feed
lesion
intestin
anim
infect
intratrach
feed
viru
also
recov
extrapulmonari
tissu
often
brain
liver
kidney
heart
infect
sentinel
cat
detect
viru
tissu
outsid
respiratori
tract
howev
patholog
chang
observ
adren
gland
one
two
sentinel
cat
infect
manner
studi
demonstr
hpai
virus
capabl
extrapulmonari
spread
cat
caus
sever
diseas
even
death
anim
infect
intratrach
feed
infect
bird
carcass
observ
also
rais
possibl
gastrointestin
tract
may
serv
sourc
hpai
infect
cat
karaca
et
al
studi
immunogen
fowlpoxbas
vaccin
cat
hai
antibodi
detect
serum
cat
follow
singl
subcutan
dose
vaccin
signific
boost
antibodi
titer
observ
follow
second
vaccin
remain
seen
cat
use
extens
evalu
vaccin
pandem
influenza
saito
colleagu
conduct
studi
evalu
replic
pathogen
influenza
virus
variou
subtyp
syrian
hamster
influenza
viru
replic
high
titer
lung
lethal
hamster
detect
brain
hpai
influenza
viru
highli
virul
mice
also
lethal
hamster
anim
succumb
infect
day
pi
mice
viru
recov
brain
infect
hamster
avian
isol
could
replic
lung
hamster
lower
titer
compar
human
isol
human
viru
elicit
low
level
neutral
antibodi
infect
hamster
wherea
avian
isol
elicit
detect
neutral
antibodi
behavior
limit
number
ai
isol
syrian
hamster
model
suggest
effect
virus
may
similar
observ
mice
evalu
model
evalu
efficaci
pandem
influenza
vaccin
warrant
renew
interest
use
nonhuman
primat
immunogen
studi
pandem
vaccin
base
presumpt
immun
respons
anim
closer
evolutionari
relationship
human
may
predict
respons
human
smaller
anim
like
mice
ferret
date
data
avail
serolog
respons
nonhuman
primat
ai
viru
vaccin
use
cynomolgu
macaqu
model
influenza
viru
infect
human
revisit
follow
emerg
highli
pathogen
ai
virus
initi
human
influenza
isol
ahong
isol
fatal
case
influenza
child
inocul
multipl
site
includ
trachea
tonsil
conjunctiva
three
four
anim
develop
fever
within
day
one
show
sign
anorexia
acut
respiratori
distress
high
titer
viru
recov
lung
day
pi
viru
also
isol
trachea
tracheobronchi
lymph
node
heart
viru
recov
tissu
day
pi
viru
also
recov
bronchioalveolar
lavag
anim
day
pi
pharyng
swab
two
anim
day
pi
nasal
swab
one
anim
day
viral
rna
detect
rtpcr
brain
two
anim
day
pi
spleen
four
anim
test
day
pi
patholog
chang
lung
infect
anim
includ
pulmonari
consolid
necrot
bronchointerstiti
pneumonia
flood
alveoli
edema
fluid
fibrin
erythrocyt
cell
debri
macrophag
neutrophil
inflammatori
chang
seen
multipl
organ
infect
rhesu
macaqu
avian
isol
report
chen
et
al
indic
result
intranas
inocul
vari
depend
influenza
viru
isol
use
clinic
sign
infect
includ
elev
bodi
temperatur
anorexia
increas
respiratori
rate
observ
macaqu
inocul
follow
virus
abarhead
agreat
patholog
chang
seen
lung
infect
anim
pronounc
monkey
inocul
duck
isol
howev
viru
reisol
infect
anim
viru
isol
respiratori
tract
secret
tissu
also
spleen
liver
heart
rhesu
macaqu
model
use
evalu
immunogen
efficaci
candid
live
attenu
coldadapt
vaccin
vaccin
viru
deriv
ha
na
clade
viru
six
intern
protein
gene
coldadapt
ca
viru
multibas
cleavag
site
ha
gene
remov
anim
inocul
intranas
vaccin
viru
day
serum
antibodi
vaccin
macaqu
detect
elisa
week
follow
first
dose
appar
boost
second
dose
four
week
first
dose
vaccin
anim
detect
level
neutral
antibodi
serum
second
dose
vaccin
hai
neutral
antibodi
detect
sera
vaccin
anim
hai
neutral
titer
heterolog
viru
two
fourfold
lower
homolog
viru
cell
respons
measur
elispot
detect
follow
second
dose
vaccin
three
week
second
vaccin
macaqu
challeng
intratrach
either
parent
viru
abar
head
viru
control
anim
symptom
ill
includ
anorexia
fever
loss
appetit
day
postchalleng
four
control
anim
euthan
day
postchalleng
remain
anim
gradual
recov
none
vaccin
anim
exhibit
clinic
sign
ill
patholog
chang
lung
unvaccin
control
anim
sever
vaccin
anim
viral
antigen
detect
cell
control
anim
viru
isol
organ
vaccin
anim
wherea
high
titer
viru
detect
respiratori
tissu
control
anim
rudenko
et
al
describ
evalu
safeti
immunogen
protect
efficaci
live
attenu
coldadapt
vaccin
viru
base
low
pathogen
viru
candid
vaccin
java
macaqu
vaccin
candid
reassort
deriv
ha
na
intern
protein
gene
donor
viru
live
attenu
influenza
vaccin
use
russia
monkey
vaccin
two
dose
coldadapt
vaccin
viru
day
apart
exhibit
sign
ill
viru
recov
anim
titer
day
first
dose
dose
vaccin
viru
use
report
coldadapt
vaccin
viru
elicit
modest
hai
respons
vaccin
macaqu
anim
challeng
hpai
isol
vaccin
anim
develop
fever
lower
grade
shorter
durat
observ
control
anim
shed
challeng
viru
occur
vaccin
anim
shorter
durat
control
anim
data
suggest
may
small
protect
effect
coldadapt
vaccin
viru
heterolog
viru
challeng
howev
number
anim
use
small
immun
respons
observ
consist
anim
coldadapt
vaccin
evalu
phase
phase
clinic
trial
small
number
volunt
vaccin
evalu
two
differ
dose
level
two
dose
found
safe
immunogen
subject
hai
antibodi
detect
serum
vaccin
recipi
iga
antibodi
detect
elisa
nasal
wash
sampl
qualit
respons
similar
observ
mous
model
level
replic
vaccin
viru
human
report
develop
live
attenu
vaccin
influenza
virus
pandem
potenti
rapidli
progress
preclin
evalu
earli
stage
clinic
test
recent
year
data
mous
ferret
model
suggest
vaccin
virus
subtyp
though
restrict
replic
respiratori
tract
compar
wildtyp
virus
elicit
serum
antibodi
respons
protect
lethal
challeng
pulmonari
extrapulmonari
replic
follow
wildtyp
viru
challeng
addit
crossprotect
heterolog
wildtyp
virus
observ
vari
degre
studi
nonhuman
primat
also
show
live
attenu
influenza
viru
vaccin
could
replic
respiratori
tract
elicit
serum
hai
respons
clinic
trial
involv
small
number
healthi
adult
live
attenu
coldadapt
vaccin
candid
base
clade
virus
ahong
found
highli
restrict
replic
poorli
immunogen
live
vaccin
viru
base
viru
administ
two
dose
per
dose
fail
elicit
neutral
antibodi
serum
vaccine
elicit
serum
hai
antibodi
studi
subject
serum
iga
nasal
wash
iga
respons
detect
subject
respect
serum
local
iga
respons
measur
ferret
studi
although
underli
reason
yet
elucid
poor
predict
valu
mous
ferret
model
respect
replic
immunogen
particular
vaccin
candid
unexpect
rudenko
et
al
report
live
attenu
coldadapt
vaccin
ha
low
pathogen
avian
viru
elicit
serum
hai
neutral
antibodi
volunt
two
dose
result
product
local
iga
respiratori
tract
vaccine
level
shed
vaccin
viru
volunt
determin
reason
superior
immunogen
ca
vaccin
viru
compar
vaccin
base
ca
small
clinic
studi
fulli
understood
possibl
donor
coldadapt
viru
use
gener
ca
vaccin
viru
less
attenu
ca
donor
viru
result
vaccin
viru
replic
effici
howev
confirm
sinc
replic
ca
vaccin
viru
human
report
given
poor
predict
valu
mous
ferret
model
respect
replic
immunogen
clade
live
attenu
vaccin
human
interest
see
coldadapt
vaccin
describ
fan
et
al
behav
human
clinic
trial
ca
vaccin
viru
highli
restrict
replic
phase
clinic
studi
elicit
immun
respons
subject
howev
serum
iga
hai
neutral
antibodi
frequent
observ
indic
immunogen
vaccin
human
serum
iga
respons
detect
subject
subject
develop
fourfold
greater
rise
hai
neutral
antibodi
respect
studi
mice
ferret
accur
predict
restrict
replic
vaccin
viru
difficult
determin
predict
valu
mous
ferret
studi
term
immunogen
sinc
number
human
subject
vaccin
evalu
small
serum
iga
respons
studi
anim
ca
vaccin
evalu
phase
clinic
trial
human
despit
highli
restrict
replic
vaccin
viru
immunogen
subject
least
one
assay
hai
neutral
assay
degre
restrict
replic
vaccin
viru
human
predict
studi
mice
emerg
pandem
influenza
viru
prompt
rapid
respons
research
commun
vaccin
manufactur
develop
vaccin
emerg
viru
inactiv
live
attenu
vaccin
base
viru
produc
use
manufactur
process
regulatori
infrastructur
season
influenza
vaccin
order
make
vaccin
avail
expediti
pandem
vaccin
evalu
limit
clinic
trial
support
licensur
extens
preclin
test
anim
perform
inactiv
live
attenu
vaccin
novel
influenza
viru
licens
septemb
us
anim
model
howev
need
continu
studi
pandem
influenza
viru
evalu
altern
approach
develop
vaccin
pathogen
sever
laboratori
report
studi
pandem
influenza
viru
isol
laboratori
anim
studi
summar
follow
section
pandem
influenza
virus
isol
human
replic
effici
respiratori
tract
balbc
mice
without
prior
adapt
howev
differ
sever
diseas
caus
isol
report
two
laboratori
main
et
al
report
isol
highli
infecti
mous
model
mous
infecti
dose
plaqu
form
unit
pfu
viru
two
isol
lethal
mice
wherea
itoh
cowork
report
viru
lethal
mice
pfu
mortal
also
observ
mice
infect
anoth
isol
pfu
studi
weight
loss
observ
mice
follow
infect
diseas
far
sever
studi
conduct
itoh
et
al
studi
peak
viru
titer
lung
day
postinfect
similar
pfu
viru
replic
restrict
respiratori
tract
higher
level
viru
replic
sever
patholog
chang
observ
lung
mice
infect
pandem
influenza
viru
compar
inocul
recent
season
human
influenza
viru
promin
bronchiti
alveol
posit
stain
viral
antigen
observ
day
pi
mice
infect
sign
regener
present
day
pi
mice
inocul
season
viru
progress
bronchiti
peribronch
day
pi
much
less
extens
stain
viru
antigen
tissu
anim
inactiv
splitvirion
vaccin
pandem
influenza
administ
without
adjuv
evalu
mice
studi
suggest
singl
dose
vaccin
requir
adjuv
elicit
serum
hai
respons
predict
protect
interim
data
human
clinic
studi
demonstr
singl
dose
ha
administ
inde
elicit
serum
antibodi
respons
predict
protect
accord
criteria
licensur
season
influenza
vaccin
howev
data
recipi
vaccin
administ
without
adjuv
report
interim
data
clinic
trial
inactiv
pandem
influenza
vaccin
suggest
surprisingli
singl
dose
unadjuv
vaccin
suffici
immunogen
meet
criteria
establish
licensur
season
influenza
vaccin
preliminari
data
clinic
trial
pandem
vaccin
show
evid
immunolog
prime
novel
viru
complex
previou
immunolog
experi
human
influenza
virus
either
prior
infect
vaccin
emul
easili
experiment
anim
replic
virul
pandem
virus
compar
recent
season
human
influenza
virus
evalu
ferret
beyond
mild
level
inact
overt
clinic
sign
influenza
observ
ferret
inocul
pronounc
clinic
featur
result
euthanasia
observ
ferret
inocul
viru
isol
texa
mexico
anim
receiv
pandem
viru
isol
wisconsin
netherland
japan
clinic
symptom
seen
ferret
reflect
sever
infect
patient
virus
isol
gener
pandem
virus
recent
season
influenza
virus
replic
effici
similar
level
upper
respiratori
tract
ferret
pandem
virus
achiev
higher
titer
lung
viru
also
detect
rectal
swab
tissu
sampl
taken
intestin
tract
infect
ferret
sporad
report
gastrointestin
symptom
human
case
pandem
influenza
infect
appear
common
signific
observ
respect
pathogenesi
infect
virus
clear
patholog
chang
observ
respiratori
tract
ferret
inocul
either
season
pandem
virus
chang
extens
sever
ferret
infect
pandem
virus
itoh
et
al
report
similar
level
viral
antigen
nasal
mucosa
anim
receiv
either
season
pandem
viru
lung
ferret
inocul
season
viru
appear
mostli
normal
wherea
ferret
sever
bronchopneumonia
promin
express
viral
antigen
peribronchi
gland
alveolar
cell
similarli
ferret
inocul
pandem
isol
netherland
mild
moder
multifoc
necrot
rhiniti
tracheiti
bronchiti
bronchiol
day
pi
viral
antigen
observ
mani
cell
nasal
caviti
trachea
bronchu
bronchiol
patholog
chang
presenc
viral
antigen
limit
upper
respiratori
tract
less
extens
respect
ferret
inocul
season
influenza
day
pi
virusinfect
cell
clear
respiratori
tract
ferret
inocul
either
season
pandem
viru
pandem
influenza
virus
also
found
effici
transmit
via
direct
contact
respiratori
droplet
summari
pandem
virus
replic
effici
season
influenza
virus
lower
respiratori
tract
ferret
increas
level
replic
associ
sever
patholog
chang
lower
respiratori
tract
gener
result
sever
clinic
ill
describ
sever
report
use
nonhuman
primat
speci
model
studi
influenza
infect
evalu
experiment
influenza
vaccin
date
one
report
infect
nonhuman
primat
pandem
influenza
virus
itoh
colleagu
studi
infect
cynomolgu
macaqu
viru
previou
studi
avian
influenza
virus
model
multipl
rout
inocul
use
establish
infect
anim
inocul
total
dose
via
intratrach
intranas
ocular
oral
rout
macaqu
inocul
viru
experienc
greater
increas
bodi
temperatur
anim
receiv
recent
season
viru
exhibit
clinic
sign
infect
pandem
viru
replic
effici
upper
lower
respiratori
tract
macaqu
achiev
titer
lung
day
pi
high
titer
viru
still
detect
oronasopharynx
tonsil
bronchi
one
anim
day
pi
clear
respiratori
tissu
patholog
chang
observ
anim
inocul
either
pandem
season
influenza
virus
lesion
sever
anim
receiv
pandem
viru
day
pi
edemat
exud
inflammatori
infiltr
alveolar
space
sever
thicken
alveolar
wall
observ
cell
appear
type
pneumocyt
posit
viral
antigen
distribut
inflammatori
lesion
mani
type
ii
pneumocyt
also
posit
viru
antigen
thicken
alveolar
wall
also
observ
larg
section
lung
monkey
infect
season
influenza
viru
promin
inflammatori
cell
alveolar
wall
howev
cell
stain
posit
viral
antigen
spars
type
type
ii
pneumocyt
day
pi
lung
patholog
remain
sever
anim
receiv
pandem
viru
infect
season
influenza
viru
mani
antigenposit
cell
still
visibl
howev
regen
chang
also
evid
despit
fact
correl
protect
ai
viru
infect
human
known
criteria
licens
pandem
influenza
vaccin
base
previou
experi
vaccin
season
influenza
europ
unit
state
regulatori
author
publish
guidanc
vaccin
manufactur
attempt
balanc
need
expedit
approv
pandem
influenza
vaccin
requir
demonstr
safeti
immunogen
candid
vaccin
unit
state
exampl
guidanc
vaccin
manufactur
publish
state
licensur
inactiv
live
attenu
vaccin
pandem
influenza
base
percent
subject
achiev
hai
antibodi
titer
greater
rate
seroconvers
defin
fourfold
greater
rise
postvaccin
hai
antibodi
titer
could
particularli
problemat
live
attenu
ai
vaccin
sinc
experi
season
live
influenza
vaccin
indic
serum
antibodi
level
correl
efficaci
vaccin
result
clinic
trial
conduct
far
live
attenu
ai
vaccin
suggest
measur
immun
respons
serum
hai
neutral
antibodi
exampl
serum
iga
level
preclin
studi
may
valu
efficaci
studi
anim
model
although
absolut
requir
may
least
provid
evid
biolog
relev
immun
respons
elicit
candid
vaccin
guidanc
intend
allow
rapid
market
approv
pandem
influenza
vaccin
produc
use
manufactur
process
alreadi
valid
season
influenza
vaccin
licensur
pandem
vaccin
essenti
strain
chang
approv
requir
much
limit
test
candid
vaccin
anim
model
european
union
manufactur
requir
submit
inform
product
preclin
test
mockup
pandem
vaccin
event
pandem
vaccin
made
way
mockup
vaccin
base
nascent
pandem
viru
produc
subject
limit
preclin
character
includ
immunogen
studi
anim
least
one
batch
product
efficaci
studi
actual
pandem
vaccin
formul
anim
requir
howev
extens
preclin
test
vaccin
candid
requir
new
vaccin
modal
formul
includ
formul
approv
vaccin
adjuv
us
regulatori
mechan
introduc
commonli
refer
anim
rule
obtain
market
approv
vaccin
efficaci
studi
healthi
human
volunt
either
uneth
feasibl
regul
stipul
case
efficaci
vaccin
human
definit
determin
market
approv
vaccin
may
grant
base
adequ
wellcontrol
anim
studi
provid
basi
vaccin
efficaci
reason
well
understood
anim
respond
vaccin
manner
predict
respons
human
studi
one
anim
speci
would
typic
requir
unless
singl
anim
model
avail
faith
predict
efficaci
vaccin
human
unclear
time
whether
rule
eventu
appli
vaccin
pandem
influenza
event
critic
predict
valu
avail
anim
model
immunogen
efficaci
pandem
influenza
vaccin
determin
systemat
use
vaccin
formul
progress
clinic
studi
although
sever
anim
speci
support
replic
human
ai
virus
survey
literatur
lead
conclus
singl
ideal
anim
model
evalu
influenza
vaccin
anim
model
suitabl
other
predict
attenu
live
viru
vaccin
close
reflect
human
immun
respons
vaccin
anim
model
certainli
play
crucial
role
evalu
influenza
vaccin
limit
model
must
taken
account
decis
regard
vaccin
candid
move
forward
clinic
trial
made
evalu
vaccin
pandem
influenza
present
addit
challeng
correl
protect
ai
virus
known
may
greater
need
relianc
data
anim
studi
vaccin
critic
behavior
ai
virus
pandem
potenti
character
rang
anim
model
even
limit
observ
clear
replic
ai
virus
abil
caus
diseas
anim
depend
host
speci
subtyp
even
strain
specif
date
level
replic
immunogen
live
attenu
ai
candid
vaccin
virus
seen
anim
model
accur
predict
behavior
vaccin
virus
human
therefor
preclin
safeti
immunogen
efficaci
data
anim
studi
must
care
consid
evalu
pandem
influenza
vaccin
